Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 266 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Artificial Tears Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Active, not recruiting Phase 2 Interventional

Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression

NCT03349528
View directory record Official record
Conditions
Bipolar Depression
Interventions
Probiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Systane Complete Multi-symptom Relief

NCT05056155
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Systane Complete
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Kansas City, Missouri • Granville, Ohio • Powell, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Intraductal Meibomian Gland Probing Trial

NCT02256969
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Blephamide, GenTeal PM Night-Time, Meibomian Gland Probing, Sham Meibomian Gland Probing
Drug · Procedure
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Systane Ultra Versus Maxidex Versus Saline

NCT01775540
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Systane Ultra, Saline solution, Maxidex
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

NCT01470118
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 20, 2026, 8:51 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Essential Oil-Based Product System for Digestive Support

NCT07653815
View directory record Official record
Conditions
Healthy
Interventions
essential oil supplement, Essential Oil, Placebo supplement, placebo essential oil
Dietary Supplement · Other
Lead sponsor
dōTERRA International
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Pleasant Grove, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed No phase listed Observational Results available

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration

NCT06445569
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
KH-1, Placebo
Dietary Supplement · Other
Lead sponsor
Kalin Health, LLC
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 20, 2026, 8:51 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Microalgae Extract Dietary Supplement on Gut Health, Anxiety, and Immune Function

NCT06425094
View directory record Official record
Conditions
Gastrointestinal Problem, Anxiety, Stress, Gastrointestinal Symptoms
Interventions
Microalgae Extract Capsules, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 4 Interventional

Tear Film Markers in Dry Eye Syndrome

NCT04515329
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine, Artificial tear
Drug
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

NCT04764669
View directory record Official record
Conditions
Lewy Body Disease, Parkinson Disease
Interventions
E2027
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Sun City, Arizona • Atlantis, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 8:51 AM EDT
Not listed Phase 1 Interventional

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

NCT04990739
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
MTB-9655
Drug
Lead sponsor
MetaboMed Inc
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

NCT03287635
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Corticotropin 80Unit/Ml Repository Injection
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

NCT01007253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

NCT06130384
View directory record Official record
Conditions
Pain, Intravitreal Injection, Pain, Acute
Interventions
Use of bromfenac 0.09% to reduce intravitreal injection pain, Use of artificial tears to reduce intravitreal injection pain
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • Bethlehem, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

NCT01817582
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial tears
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 20, 2026, 8:51 AM EDT